Posted by Michael Wonder on 20 Mar 2026
Bristol Myers Squibb transforms the classical Hodgkin lymphoma treatment paradigm with expanded US and EMA approvals for Opdivo (nivolumab)
20 March 2026 - Bristol Myers Squibb today announced that Opdivo (nivolumab) has received approval for two new classical Hodgkin lymphoma indications in the US and the European Union (EU).
The US FDA granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and paediatric patients 12 years and older with previously untreated, stage III or IV classical Hodgkin lymphoma.
In the EU, the European Commission approved Opdivo in combination with brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory classical Hodgkin lymphoma after one prior line of therapy.
